[The triglyceride-lowering effects of PCSK9 inhibitor differ in patients with different baseline triglyceride levels]

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Hypertriglyceridemia is a significant risk factor for cardiovascular disease.
• PCSK9 inhibitors are a novel class of lipid-lowering agents.
• Understanding the efficacy of PCSK9 inhibitors across different triglyceride levels is crucial.

Purpose of the Study:

• To evaluate the triglyceride-lowering efficacy of PCSK9 inhibitors in patients stratified by baseline triglyceride levels.
• To determine if baseline triglyceride levels influence the response to PCSK9 inhibitor therapy.

Main Methods:

• A cohort of 59 patients receiving PCSK9 inhibitor (Evolocumab) was analyzed.
• Patients were categorized into four groups based on baseline triglyceride levels: normal, mild, moderate, and severe hypertriglyceridemia.
• Changes in triglyceride levels post-treatment were compared among the groups.

Main Results:

• PCSK9 inhibitor treatment significantly reduced triglyceride levels in patients with moderate (2.30-5.63 mmol/L) and severe (≥5.64 mmol/L) hypertriglyceridemia (P < 0.005).
• No significant changes in triglyceride levels were observed in patients with normal (< 1.70 mmol/L) or mild (1.70-2.29 mmol/L) baseline hypertriglyceridemia.

Conclusions:

• PCSK9 inhibitors demonstrate significant efficacy in reducing triglyceride levels for patients with moderate to severe hypertriglyceridemia.
• The therapeutic benefit of PCSK9 inhibitors regarding triglyceride reduction is limited in patients with normal or only mildly elevated baseline triglyceride levels.